Rosie Bernard
Senior Production & Content Director, Informa Connect
UK biotech is thriving with record investment and faster trials. The challenge now: scaling success before advantages slip away.
Britain’s life sciences sector is showing what happens when the right conditions align. Since the Life Sciences Sector Plan launched in 2025, the sector has attracted over £3 billion in new investment and clinical trial set-up time has fallen from 169 to 122 days. By Q2 2026, UK biotech VC investment reached £2.05 billion, capturing 61% of all European biotech VC.
Building on a legacy of innovation
From penicillin to Dolly the sheep, Britain has never lacked world-changing science. Cambridge, the Golden Triangle and Manchester continue to produce it. The NHS offers unrivalled real-world data as AI-driven drug discovery accelerates globally, with both the US and China competing for clinical trial dominance.
What’s changing: regulatory fast-tracking, a US pharmaceutical market access arrangement, and new investment vehicles closing the discovery-to-commercialisation gap.
Without viable exit routes,
today’s VC surge risks becoming stranded capital
Fragility beneath the boom
But momentum masks vulnerabilities. Investment slowly flows into early-stage ventures, yet pharmaceutical exports are falling, and biotech IPOs collapsed from 10 in 2021 to just one in 2024. Without viable exit routes, today’s VC surge risks becoming stranded capital. A narrowing STEM pipeline and risk-averse institutional investors compound the challenge.
Staying ahead
Patient capital through pension fund mandates, procurement reform rewarding homegrown innovation and empowered regional clusters aren’t optional — they convert short-term gains into sustained leadership. Britain has proven the model works; the next year will determine if it scales before competitors close the gap.
